Progress in Cardiovascular Pharmacology

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1155

Special Issue Editors


E-Mail Website
Guest Editor
Cardiology Department, Perinei Hospital, Bari, Italy
Interests: noninvasive assessment; heart failure; arrhythmias; preventive cardiology; cardiovascular pharmacology; cardio-oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiovascular diseases (CVDs) still represent the main cause of death worldwide, with increasingly higher rates being reported in the literature. More specifically, the influence of CVD on quality of life is even more dramatic, as the loss in quality-adjusted life years (QALYs) negatively impacts economics as well due to direct and indirect costs related to reduced skills in performing daily activities.

Recently, innovations in cardiologic treatments have represented the cornerstone for reversing the impact of CVD on the overall prognosis of patients, with noninvasive approaches providing interesting insights on counteracting disease progression and the worsening of alterations in cardiac and vascular structures and function.

The most intriguing research efforts are now concentrating on a molecular approach to CVD, based on techniques regulating gene transcription and—in the near future—influencing protein transduction and gene editing.

The final goal of pharmacological innovations is to provide therapies tailored to a single patient’s clinical characteristics by identifying and modifying genetic abnormalities, restoring the original function.

The scientific community looks forwards to hearing and learning these new approaches to diseases, particularly CVD.

The aim of this Special Issue is to provide the most recent advances in pharmacological approaches to CVD to define their future impact on patient prognosis and the reversal of clinical outcomes.

Prof. Dr. Pietro Scicchitano
Dr. Francesco Massari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular diseases
  • cardiovascular pharmacology
  • target therapies
  • molecular pharmacology
  • heart failure
  • preventive cardiology
  • atherosclerosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1223 KiB  
Review
Inferior Vena Cava Filter in Cancer-Associated Thrombosis: A Vade Mecum for the Treating Physicians: A Narrative Review
by Agnese Maria Fioretti, Daniele La Forgia, Pietro Scicchitano, Natale Daniele Brunetti, Riccardo Inchingolo, Carlo Gabriele Tocchetti and Stefano Oliva
Biomedicines 2024, 12(10), 2230; https://doi.org/10.3390/biomedicines12102230 - 30 Sep 2024
Viewed by 911
Abstract
Cancer is a remarkable prothrombotic disease, and cancer-associated thrombosis acts as a dreadful omen for poor prognosis. The cornerstone of venous thromboembolism therapy is anticoagulation; however, in patients with venous thromboembolism who are not suitable for anticoagulation (contraindication, failure, or complication), the inferior [...] Read more.
Cancer is a remarkable prothrombotic disease, and cancer-associated thrombosis acts as a dreadful omen for poor prognosis. The cornerstone of venous thromboembolism therapy is anticoagulation; however, in patients with venous thromboembolism who are not suitable for anticoagulation (contraindication, failure, or complication), the inferior vena cava filter appears a valuable option in the therapeutic arsenal. The recently heightened trend of steady rise in filter placement mirrors the spread of retrievable devices, together with improvements in physicians’ insertion ability, medico-legal issue, and novel and fewer thrombogenic materials. Nevertheless, the exact role of the inferior vena cava filter in cancer has yet to be endorsed due to a dearth of robust evidence. Indeed, data that support the inferior vena cava filter are weak and even controversial, resulting in discrepancies in the interpretation and application of guidelines in daily practice. In this narrative review, we aim at clarifying the state of the art on inferior vena cava filter use in malignancies. Furthermore, we provide a feasible, conclusive 4-step algorithm for the treating physicians in order to offer a practical strategy to successfully employ the inferior vena cava filter as a priceless device in the current armamentarium against cancer. Full article
(This article belongs to the Special Issue Progress in Cardiovascular Pharmacology)
Show Figures

Figure 1

Back to TopTop